Ropes & Gray Advises Takeda in Innate Pharma Worldwide License of Antibodies for Celiac Disease Research Program

In The News
April 3, 2023

Ropes & Gray advised Takeda Pharmaceutical Company Limited in a license agreement under which Innate Pharma SA grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) with a primary focus in Celiac disease. Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies. The transaction was announced on April 3.

Under the terms of the license agreement, Innate is eligible to receive up to $410 million in future development, regulatory and commercial milestones if all milestones are achieved during the term of the agreement, plus royalties on potential net sales of any commercial product resulting from the license.

The Ropes & Gray team included IP transactions partner Hannah England and IP transactions associate Ian Nilsen.